1. Home
  2. SNFCA vs IKT Comparison

SNFCA vs IKT Comparison

Compare SNFCA & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Security National Financial Corporation

SNFCA

Security National Financial Corporation

HOLD

Current Price

$8.84

Market Cap

234.1M

Sector

Finance

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.73

Market Cap

201.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNFCA
IKT
Founded
1965
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
234.1M
201.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SNFCA
IKT
Price
$8.84
$1.73
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$6.00
AVG Volume (30 Days)
28.5K
601.2K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.74
N/A
Revenue
$340,876,482.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.77
N/A
Revenue Growth
3.25
N/A
52 Week Low
$7.32
$1.33
52 Week High
$12.83
$3.32

Technical Indicators

Market Signals
Indicator
SNFCA
IKT
Relative Strength Index (RSI) 49.99 50.54
Support Level $8.67 $1.61
Resistance Level $9.28 $1.88
Average True Range (ATR) 0.26 0.13
MACD -0.00 -0.02
Stochastic Oscillator 54.44 23.66

Price Performance

Historical Comparison
SNFCA
IKT

About SNFCA Security National Financial Corporation

Security National Financial Corp is engaged in the life insurance, cemetery and mortuary, and mortgage loan businesses. The life insurance segment is engaged in the business of selling and servicing selected lines of life insurance, annuity products, and accident and health insurance. Its cemetery and mortuary segment consists of approximately seven mortuaries and five cemeteries in the state of Utah and a cemetery in the state of California. The mortgage loan segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and real estate projects. Geographically, all the business activity is functioned through the region of the USA and it derives the majority of revenue from Mortgage segment.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: